NovavaxXSWX:NVAX -1.78%50 Gross Margin % is 78.00% as of Mar. 2026, which is 37% above its 10-year median of 56.92. GuruFocus rates XSWX:NVAX with a GF Score™ of 50/100 and a GF Value™ of CHF3.14. The stock has 7 warning signs investors should review. Among 730 Biotechnology companies, Novavax ranks better than 77.81% on this metric.
Gross Margin % is calculated as gross profit divided by its revenue. Novavax's Gross Profit for the
three
months ended in Mar. 2026 was CHF85.7 Mil. Novavax's Revenue for the
three
months ended in Mar. 2026 was CHF109.8 Mil. Therefore, Novavax's Gross Margin % for the quarter that ended in Mar. 2026 was 78.00%.
The historical rank and industry rank for Novavax's Gross Margin % or its related term are showing as below:
XSWX:NVAX'
s Gross Margin % Range Over the Past 10 Years
Min: 38.21 Med: 56.92 Max: 93.5
Current: 84.97
During the past 13 years, the highestGross Margin % of Novavax was 93.50%. The lowest was 38.21%. And the median was 56.92%.
XSWX:NVAX's Gross Margin % is ranked better than 77.81% of 730
companies
in the Biotechnology industry
Industry Median: 60.91
vs XSWX:NVAX: 84.97
Novavax had a gross margin of 78.00% for the quarter that ended in Mar. 2026 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Novavax was 0.00% per year.
Novavax (XSWX:NVAX) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Novavax had a gross margin of 78.00% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Novavax Gross Margin % Related Terms
Novavax Gross Margin % Historical Data
* Premium members only.
The historical data trend for Novavax's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:NVAX vs MPLT, COAG, INBX: Gross Margin % Comparison
For the Biotechnology subindustry, Novavax's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Novavax Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Novavax's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Novavax's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Novavax (XSWX:NVAX) has a Gross Margin % of 78.00% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Novavax and its competitors. This is 37% above median its historical median of 56.92. Over the past decade, Novavax's Gross Margin % has ranged from 38.21 to 93.50. According to the industry distribution chart, Novavax ranks #162 out of 730 companies in the Biotechnology industry, placing it in the top 22.2%.
Is Novavax's Gross Margin % too high?
Novavax's current Gross Margin % of 78.00% is 37% above median its 10-year median of 56.92. Over the past 10 years, this metric has ranged from a low of 38.21 to a high of 93.50. The Biotechnology industry median Gross Margin % is 60.91. Novavax's value of 78.00% is 28.1% above this industry median. Based on the distribution chart, Novavax ranks #162 out of 730 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Novavax has a GF Score™ of 50/100, reflecting its overall financial health beyond just this single metric.
How does Novavax's Gross Margin % compare to MPLT and COAG?
According to the Biotechnology industry distribution chart, Novavax ranks #162 out of 730 companies for Gross Margin %. This places Novavax in the top 22% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 60.91. Novavax's value of 78.00% is 28.1% above this benchmark. Historically, Novavax's own Gross Margin % has ranged from 38.21 to 93.50 over the past decade. While the company's 10-year median is 56.92 vs. the industry median of 60.91, Novavax has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.91, based on 730 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Novavax's current Gross Margin % of 78.00% is 28.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Novavax and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Novavax's current Gross Margin % is 78.00%, which is 37% above median its own 10-year median of 56.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novavax stock overvalued right now?
Novavax (XSWX:NVAX) has a current Gross Margin % of 78.00%. The stock's GF Value™ is CHF3.14, compared to a current price of CHF7.61 — trading 142.4% above its estimated fair value. The current Gross Margin % is 78.00%, which is 37% above median its 10-year median of 56.92 and 28.1% above the Biotechnology industry median of 60.91. Novavax's overall GF Score™ is 50/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Novavax (XSWX:NVAX), the current Gross Margin % is 78.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Novavax (XSWX:NVAX) Overvalued in 2026?
Based on GuruFocus' analysis, Novavax stock appears to be overvalued.
The current stock price of CHF7.61 is trading 142.4% above its estimated GF Value™ of CHF3.14.
Key valuation signals for XSWX:NVAX:
Gross Margin %: 78.00% (37% above median its 10-year median of 56.92)
GF Value™: CHF3.14 vs. price of CHF7.61 (142.4% above fair value)
Industry Position: 28.1% above the Biotechnology median (#162 of 730)
No single metric tells the full story. See the XSWX:NVAX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.
50GF Score
Get the complete analysis for XSWX:NVAX
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:NVAX has been successfully added to your 
